Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals (NASDAQ: RIGL) has announced the granting of inducement awards to new employees under NASDAQ Listing Rule 5635(c)(4). The company granted a total of 23,075 stock options and restricted stock units to 10 non-executive employees. These equity awards will vest over a four-year period with a one-year cliff.
Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals (NASDAQ: RIGL) ha annunciato la concessione di premi di incentivazione a nuovi dipendenti ai sensi della Regola NASDAQ 5635(c)(4). La societ脿 ha assegnato un totale di 23.075 opzioni su azioni e unit脿 azionarie vincolate a 10 dipendenti non dirigenti. Questi premi azionari matureranno nell'arco di quattro anni con un periodo di vesting iniziale di un anno.
Rigel, fondata nel 1996 e con sede a South San Francisco, 猫 un'azienda biotecnologica focalizzata sullo sviluppo di terapie per disturbi ematologici e il cancro.
Rigel Pharmaceuticals (NASDAQ: RIGL) ha anunciado la concesi贸n de premios de incentivo a nuevos empleados conforme a la Norma de Listado NASDAQ 5635(c)(4). La compa帽铆a otorg贸 un total de 23,075 opciones sobre acciones y unidades restringidas de acciones a 10 empleados no ejecutivos. Estas concesiones de acciones se consolidar谩n durante un per铆odo de cuatro a帽os con un per铆odo inicial de un a帽o.
Rigel, fundada en 1996 y con sede en South San Francisco, es una empresa biotecnol贸gica centrada en desarrollar terapias para trastornos hematol贸gicos y c谩ncer.
Rigel Pharmaceuticals (NASDAQ: RIGL)電� NASDAQ 靸侅灔 攴滌箼 5635(c)(4)鞐� 霐半澕 鞁犾瀰 歆侅洂霌れ棎瓴� 鞙犾澑 氤挫儊鞚� 攵�鞐枅雼り碃 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 10氇呾潣 牍勳瀯鞗� 歆侅洂鞐愱矊 齑� 23,075欤检潣 鞀ろ啞鞓奠厴 氚� 鞝滍暅 欤检嫕 雼渼毳� 攵�鞐枅鞀惦媹雼�. 鞚� 欤检嫕 氤挫儊鞚� 1雲� 韥措Μ頂� 旮瓣皠鞚� 韽暔頃� 4雲勱皠鞐� 瓯胳硱 甓岆Μ臧� 旆摑霅╇媹雼�.
1996雲勳棎 靹る霅橃柎 靷毎鞀� 靸岉攧霝�鞁滌姢旖旍棎 氤胳偓毳� 霊� Rigel鞚� 順堨暋 歆堩櫂 氚� 鞎� 旃橂鞝� 臧滊皽鞐� 欤茧牓頃橂姅 靸濍獏瓿淀暀 須岇偓鞛呺媹雼�.
Rigel Pharmaceuticals (NASDAQ : RIGL) a annonc茅 l鈥檃ttribution de primes d鈥檌ncitation 脿 de nouveaux employ茅s conform茅ment 脿 la r猫gle NASDAQ 5635(c)(4). La soci茅t茅 a accord茅 un total de 23 075 options d鈥檃chat d鈥檃ctions et unit茅s d鈥檃ctions restreintes 脿 10 employ茅s non cadres. Ces attributions d鈥檃ctions seront acquises sur une p茅riode de quatre ans avec un cliff d鈥檜n an.
Fond茅e en 1996 et bas茅e 脿 South San Francisco, Rigel est une entreprise de biotechnologie sp茅cialis茅e dans le d茅veloppement de th茅rapies pour les troubles h茅matologiques et le cancer.
Rigel Pharmaceuticals (NASDAQ: RIGL) hat die Gew盲hrung von Anreizpr盲mien an neue Mitarbeiter gem盲脽 NASDAQ-Listing-Regel 5635(c)(4) bekannt gegeben. Das Unternehmen gew盲hrte insgesamt 23.075 Aktienoptionen und Restricted Stock Units an 10 nicht gesch盲ftsf眉hrende Mitarbeiter. Diese Aktienverg眉tungen werden 眉ber einen Zeitraum von vier Jahren mit einer einj盲hrigen Sperrfrist vesten.
Rigel, gegr眉ndet 1996 und mit Sitz in South San Francisco, ist ein Biotechnologieunternehmen, das sich auf die Entwicklung von Therapien f眉r h盲matologische Erkrankungen und Krebs spezialisiert hat.
- None.
- None.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media
Rigel Pharmaceuticals, Inc.听
650.624.1232
[email protected]
听
View original content to download multimedia:
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
What inducement grants did Rigel Pharmaceuticals (RIGL) announce in July 2025?
How many employees received inducement grants from Rigel (RIGL) in July 2025?
What is the vesting schedule for Rigel's (RIGL) July 2025 inducement grants?
What is Rigel Pharmaceuticals' (RIGL) main business focus?
